New drug combo targets tough liver and kidney cancers
NCT ID NCT07494435
First seen Mar 28, 2026 · Last updated May 07, 2026 · Updated 5 times
Summary
This study tests a new drug called WGI-0301 combined with nivolumab in people with advanced liver or kidney cancer. The goal is to see if the combination is safe and shows signs of shrinking tumors. About 230 adults aged 18 to 75 will take part at multiple hospitals, with no placebo used.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATO CELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China Pharmaceutical University, Shanghai Gobroad Cancer Hospital
Shanghai, Shanghai Municipality, 200131, China
Conditions
Explore the condition pages connected to this study.